Automated Insulin Pump in Type 2 Diabetes

This editorial discusses the potential of automated insulin delivery (AID) systems for patients with type 2 diabetes, based on a clinical trial by Kudva et al. The trial involved 319 insulin treated patients with type 2 diabetes, randomized to use the t:slim X2 insulin pump with Control IQ technology or continue their current insulin therapy. Results showed a significant reduction in glycated hemoglobin levels (from 8.2% to 7.3%) and improved time in range glucose metrics in the AID group, with a low risk of adverse events. Despite challenges like cost, training demands, and healthcare system strain, the study highlights AID as a promising advancement for type 2 diabetes management.

This editorial discusses the potential of automated insulin delivery (AID) systems for patients with type 2 diabetes, based on a clinical trial by Kudva et al. The trial involved 319 insulin treated patients with type 2 diabetes, randomized to use the t:slim X2 insulin pump with Control IQ technology or continue their current insulin therapy. Results showed a significant reduction in glycated hemoglobin levels (from 8.2% to 7.3%) and improved time in range glucose metrics in the AID group, with a low risk of adverse events. Despite challenges like cost, training demands, and healthcare system strain, the study highlights AID as a promising advancement for type 2 diabetes management.